KeyBanc analyst Paul Knight lowered the firm’s price target on Bio-Techne to $80 from $115 and keeps an Overweight rating on the shares. The firm notes the company reported a revenue and earnings miss, with results largely linked to China as the remaining businesses drove MSD/HSD organic growth, with overall organic growth of about 2%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TECH:
